Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Apple

AbbVie

Alphabet

Johnson & Johnson

Eli Lilly

Mastercard

NVIDIA

Walmart

September has historically been the weakest month for the U.S. stock market, and 2022 was no different.

These Were The Five Best And Worst Performing Mega-Cap Stocks In September 2022

Chevron

Microsoft

UnitedHealth Group

Apple and Microsoft are among the Dow Jones stocks to watch in October. The post 5 Dow Jones Stocks To Watch In October: Apple Rebounds appeared first on Investor's Business Daily.

5 Dow Jones Stocks To Watch In October: Apple Rebounds

Alector Inc

Caterpillar

Celsius Holdings

Clearfield

Invesco Treasury Collateral ETF

Dow Inc

Enphase Energy

G1 Therapeutics

Intrepid Potash

JPMorgan Chase & Co

McDonald's

Direxion Daily Semiconductor Bull 3x Shares

SPDR S&P 500 ETF Trust

TravelCenters of America

Tidewater

Direxion Daily Utilities Bull 3X Shares

Viridian Therapeutics

Wave Life Sciences

Zymeworks Inc

Two new Breakout Stocks for Week 40 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +105.6% YTD. This week 2 picks beat 10% in less than a week with FUSN +12.2%, LRMR at +12.95% and VYGR +9.2% peak gains continuing in high negative Momentum Gauge warnings.

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

Cancer drug Lynparza received an approval in China to treat patients with a type of ovarian cancer.

What This News Means for Merck

Abbott Labs

Acadia Healthcare

AstraZeneca

Bristol-Myers

Cardinal Health

Cigna

CVS Health

Novavax

Novartis

Pfizer

Regeneron Pharmaceuticals

Teladoc

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-release).

U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, October 27. During the call, company executives will provide an overview of Merck's performance for the quarter and outlook. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, a

Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27

The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.

Merck's (MRK) Keytruda Gets Four New Approvals in Japan

These businesses might be slightly "boring," but that may just be a good thing in today's market.

Bear Market: 2 Safe Stocks to Buy Right Now

Boeing

Costco

Goldman Sachs

It may not occur to investors to look for blue-chip sleeper stocks, since they don't often think of blue-chips as “sleepers.” In tough times, seasoned investors seek comfort in the stability and safety that well-established robust companies can offer.

7 Blue-Chip Sleeper Stocks to Buy Before Wall Street Wakes Up

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that it has completed a minority investment in LeeO Precision Farming B.V. (LeeO). Merck Animal Health also will assume distribution of LeeO's digital swine traceability solution in selected markets over the coming months. Merck Animal Health joins LeeO's existing founders and shareholders, Pra

Merck Animal Health Completes Minority Investment in LeeO Precision Farming

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck's KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

American Express

Home Depot

Procter & Gamble

Walgreens

While investors might not desire anything less than the most exciting investment opportunities following the wild ride last year, 2022 may be the moment for Dow sleeper stocks to buy. After all, the companies listed in the Dow 30 didn't get there as part of a fly-by-night operation.

7 Dow Sleeper Stocks to Buy Before Wall Street Wakes Up

4 top healthcare stocks for your second-half of 2022 watchlist.

Good Stocks To Buy Right Now? 4 Healthcare Stocks To Know

Amgen

Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.

Dow Jones ETF Avoids Bear Market: 4 Stocks in Green

Fusion Pharmaceuticals

Larimar Therapeutics Inc

Two new Breakout Stocks for Week 39 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +108.7% YTD. This week no picks beat 10% gains in less than a week with SLCR peak at +7.1% and continuing the highest negative Momentum Gauges® warning levels since July.

MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge

Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United States

Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

With Seagen News Lacking, Is Merck Stock A Buy Or A Sell?

Merck stock jumped Thursday after the company won a patent battle against generic-drug maker Viatris over an ingredient used in diabetes meds. The post Merck Stock Surges After Winning Patent Battle Vs.

Merck Stock Surges After Winning Patent Battle Vs. Viatris Over Two Key Drugs

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that it has signed a definitive agreement under which Merck Animal Health will acquire Vence from its founders and shareholders. Vence is an innovator in virtual fencing for rotational grazing and livestock management. The acquisition is expected to be completed in the third quarter of 2022, su

Merck Animal Health to Acquire Vence

News for Merck Stock (MRK)